FDA approves Hyqvia for chronic inflammatory demyelinating polyneuropathy

The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme’s Enhanze drug delivery technology, to treat chronic inflammatory demyelinating polyneuropathy in adults.
According to a Takeda press release, Hyqvia is the only currently available FDA-approved combination of immunoglobulin (IG) and hyaluronidase for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Hyqvia’s subcutaneous route of delivery allows it to be administered by a health care professional in the office, at an infusion center or at home, or self-administered after appropriate

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart